Tuberculosis is a global health problem that causes the death of approximately 1.5 million
people worldwide each year (WHO, p. 1–126, Global Tuberculosis Report, 2015). Treatment …

Rifampicin was discovered in 1965 and remains one of the most important drugs in
tuberculosis treatment that is valued for its sterilizing activity and ability to shorten treatment …

Rationale: We examined whether increased rifampin doses could shorten standard therapy
for tuberculosis without increased toxicity. Objectives: To assess the differences across three …

The introduction of rifampicin (rifampin) into tuberculosis (TB) treatment five decades ago
was critical for shortening the treatment duration for patients with pulmonary TB to 6 months …

Metrics commonly used to describe antibiotic efficacy rely on measurements performed on
bacterial populations. However, certain cells in a bacterial population can continue to grow …

We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the
19th century. However, Mycobacterium tuberculosis complex (MTBC) strains are still the …

Given the global burden of tuberculosis, shortened treatment regimens with existing or
repurposed drugs are needed to contribute to tuberculosis control. The long duration of …

Introduction: One-third of the world's population is infected with Mycobacterium tuberculosis
(M. tb.). Latent tuberculosis infection (LTBI) can progress to tuberculosis disease, the leading …

Background The currently recommended rifampicin dose (10 mg/kg) for treating tuberculosis
is suboptimal. The PanACEA HIGHRIF1 trial evaluated the pharmacokinetics and early …

Introduction: WHO global strategy is to end tuberculosis epidemic by 2035. Pharmacokinetic
and pharmacogenetic studies are increasingly performed and might confirm their potential …